1. No category

“Swiss-China Life Sciences Seminar”
April 8, 2015 | Technologiepark Basel
The China Business Platform (CBP) is going to put its focus on Life Sciences in the
coming season with a Life Sciences Seminar in April and a Life Sciences mission to
Shanghai in May where we will attend the Sino-Euro BioPartnering Conference with a
group of biotech companies from Basel.
At our event in April we are very honored to receive a group of special guests from
China – a top management delegation from Yangtze River Pharmaceutical Group, No. 1
Chinese pharmaceutical company in operational performance and Mr. Gao Ronghui,
CEO of G-med Consulting. They will share some valuable industry insights with us.
Furthermore, we will be joined by Dr. Heiko Visarius, CEO of Visartis Healthcare GmbH
who will talk about his real life experiences in emerging medtech markets. A panel
discussion at the end of the event will allow for an interactive discussion with the
audience.
Programme
16:00
16:10
16:40
17:10
17:40
18:20
18:30
Opening and Brief Introduction
by Mr. Gabriel Schweizer, General Manager of China Business Platform
by Mr. Fabian Käser, Manager Medtech of i-net Innovation Networks
China and other Emerging Markets – Challenges and Opportunities
Q&A
by Dr. Heiko Visarius, CEO of Visartis Healthcare GmbH
Company Presentation / Local Demand vs. Swiss Supply
Q&A
by Representative of Yangtze River Pharmaceutical Group
Critical Factors to Form an Effective Partnership with a Chinese Company
Q&A
by Mr. Gao Ronghui, CEO of G-Med Consulting
Panel Discussion on Collaboration between Swiss and Chinese Companies
with Dr. Heiko Visarius, Mr. Gao Ronghui, Mr. Xu Jingren, Mr. Peter Sorg
Moderated by Ms. Fanna Kong, Project Manager of China Business Platform
Closing
by Mr. Gabriel Schweizer, General Manager of China Business Platform
Networking Apéro
When:
Wed, April 8, 2015 (16.00 – 18:30 & Apéro)
Where:
Medartis AG, Hochbergerstrasse 60 E, 4057 Basel (next to Technologiepark Basel)
Target Group:
Business people interested in learning about the Chinese Life Sciences market,
networking with Chinese companies and doing business in China (approx. 70 people)
1/2
About Our Speakers and Panelists
Dr. Heiko Visarius, CEO, Visartis Healthcare
Dr. Heiko Visarius is an executive with 20 years of international experience in the health care
sector, especially in the area of medical device technology. A Ph.D. in engineering obtained in
the USA and a Swiss/US MBA degree combined with his professional experience allow him to
relate to a broad spectrum of business areas, such as sales, marketing, R&D, finance, supply
chain and general management. Dr. Heiko Visarius served as CEO of a successful start-up
company with an associated exit. Since then, he held various leadership positions with global
players of the medical device industry. He had P/L responsibility in Europe for a 3-digit million
USD revenue volume in a direct operation. Since 2012, he is owner of VISARTIS Healthcare
GmbH. In addition, Dr. Visarius is board member of several companies (medical devices) and an
international business school. http://www.visartis-healthcare.ch/
Mr. Jingren Xu, Chairman, CEO and founder of Yangtze River Pharma Group
From 1971 till now, Mr. Xu has developed Yangtze River Pharmaceutical Group into a leading
China-based pharmaceutical enterprise, which covers product development, manufacturing,
distribution and promotion of healthcare products. Mr. Xu serves as the Standing Director of
Chinese Medical Association, Vice President of China Association for Traditional Chinese
Medicine, Vice President of China Association of licensed Pharmacists, President of Jiangsu
Pharmaceutical Professional Association, Director of China Pharmaceutical University, Director
of Nanjing University, Visiting Professor of Nanjing University of Traditional Chinese Medicine.
http://www.yangzijiang.com/en/index.aspx
Mr. Gao Ronghui, Founder and CEO, G-Med Consulting
Mr. Gao Ronghui has more than twenty years work experience in the life science industry. He
started his career on infectious disease management before he joined Nestle as a regional leader
in the nutritional division. He then moved to the UK and joined a pharmaceutical consulting
firm, where he consulted a number of multinational pharmaceutical companies on product
launch and portfolio management. After relocating back to China, Mr.Gao joined BioBay and
China Medical City, two fast growing life science parks in China, as a Business Development
Director and Deputy Commissioner respectively. Mr. Gao is the founder and Managing Director
of G-Med Consulting. He is also an advisor to major European Bio-Clusters for their operation
in China. Additional to his medical degree, Mr. Gao holds an MBA from Manchester Business
School. [email protected], www.sebp-china.com
Peter Sorg, MD of Sorg Consulting, Senior Consultant to BVCF Europe
Mr. Sorg has more than 20 years of international senior executive management experience
(1979-2001) in the pharmaceuticals/chemicals industry with Ciba-Geigy, Novartis, Ciba SC,
including 12 years (1981-1993) in the Asia-Pacific Region. Since 2001 he is independent
entrepreneur and consultant in the life science industry focusing on technology business
development, strategic assembly and M&A. He is a former BoD member of the the Swiss-Asian
Chamber of Commerce; founder, investor and BoD member in various Biotech companies as
well as part time faculty member of the “Sino-Swiss Management Training Program” at the
University of St.Gallen. Since 2015, Peter Sorg is representing BVCF (BioVedaChinaFund) in
Europe. BVCF is the first and leading PE and growth capital investor specializing in the China Life
Science and Healthcare Industry. www.quilt-solutions.com, www.bvcf.com
About Yangtze River Pharmaceutical Group
Yangtze River Pharmaceutical Group (YRPG) is a large cross-regional pharmaceutical group established in 1971 with 40
years history in China. It owns more than 20 subsidiary companies and has more than 9,300 employees, 13.5 billion RMB
(2bn US Dollars) total assets. The facilities cover 2 million square meters and the sales network spans all of China. The main
products of YRPG are Traditional Chinese Medicines, western medicines and biological agents. YRPG was awarded the title
of “Innovative Enterprise” in 2008, “Top 500 Chinese Enterprises” and the operational performance of the Group has
achieved top 1 among Chinese Pharmaceutical Industry for many years continuously.
http://www.yangzijiang.com/en/index.aspx
If you have any questions, please contact:
Gabriel Schweizer
General Manager
Tel.: +41 61 633 22 38
[email protected]
Fanna Kong
Project Manager
Tel.: +41 61 633 22 39
[email protected]
2/2